Even with prophylactic HPV vaccines protecting against new infections, millions of people worldwide already harbor high-risk HPV strains driving cervical and oropharyngeal cancers — and for them, vaccines offer no therapeutic benefit. A molecular strategy that disarms the virus's own survival machinery inside existing cancer cells represents a fundamentally different therapeutic angle, one this research begins to map in meaningful detail.
The study, published in PNAS, targets HuB and HuR — two RNA-binding proteins from the ELAVL family — that HPV-associated cancer cells appear to co-opt to stabilize the viral oncoproteins E6 and E7. These two proteins are central executioners of HPV-driven malignancy: E6 degrades p53 (the cell's primary tumor suppressor) while E7 inactivates retinoblastoma protein, collectively releasing the brake on uncontrolled proliferation. By pharmacologically inhibiting HuB and HuR, the researchers demonstrated that E6 and E7 mRNA stability was disrupted, protein levels fell, p53 was re-stabilized, and an integrated stress response was triggered — collectively impairing cervical cancer cell viability in experimental models.
This finding is notable for several reasons beyond its mechanistic elegance. RNA-binding proteins have long been considered difficult drug targets, yet the ELAVL family has been attracting growing attention precisely because cancer cells seem unusually dependent on them for sustaining oncogenic gene expression. The dual role of HuB and HuR as post-transcriptional stabilizers of viral — not just cellular — oncogene transcripts is a relatively underexplored vulnerability. That said, significant caveats apply: available data appear to be from cell-line experiments, and the leap from cultured cervical cancer cells to human therapeutic application involves formidable hurdles around delivery, selectivity, and systemic toxicity. This is early-stage, mechanistic science. Still, for the large population living with established HPV-associated cancers beyond vaccine reach, identifying druggable nodes in viral oncoprotein maintenance is genuinely important incremental progress.